Signaling through hepatocyte vasopressin receptor 1 protects mouse liver from ischemia-reperfusion injury.

ABSTRACT: Terlipressin has been used extensively in the management of certain complications associated with end-stage liver diseases (ESLDs). In our pilot study, terlipressin treatment showed beneficial effects on liver function in patients with decompensated cirrhosis, however whether it plays a role in liver ischemia-reperfusion injury (IRI) remains unknown. Using a mouse nonlethal hepatic IR model, we found terlipressin administration significantly ameliorated IR-induced liver apoptosis, necrosis and inflammation. Furthermore, despite its known effect on visceral vasoconstriction, hemodynamic evaluation of murine hepatic tissue after IR revealed no change of overall hepatic blood flow after terlipressin treatment. Further studies identified the upregulation of vasopressin receptor 1 (V1R) express

SUBMITTER: Liu X 

PROVIDER: S-EPMC5342477 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature